SLC5A2 and cardiovascular disorder: In particular, the 2018 ADA–EASD consensus report and subsequent updates recommended GLP-1 receptor agonists and SGLT-2 inhibitors for patients with established cardiovascular disease or high-risk profiles, regardless of HbA1c levels.